Navigation Links
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease


Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain Plaque and Empower Rat Brain Cells to Recover Memory Function

In Vivo 'Proof of Concept' Study Proposes Direct Correlation Between Removing Beta Amyloid Plaque and Memory Recovery

LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in-vitro data and suggests Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's.

The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills. Plaque can cause swelling and bumps on nerve cells, making it hard or even impossible for the cells to communicate. While the cause of Alzheimer's disease still remains unknown, a growing number of researchers are indicating that plaque formation and accumulation may play a role.

The study was conducted by Samaritan's collaborating researchers, including Dr. Laurent Lecanu and Dr. Vassilios Papadopoulos.

Abstract:

www.samaritanpharma.com/caprospinol_abstract.pdf

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "Memory recovery in rats is a lot simpler than curing Alzheimer's disease in people but these study results are extremely encouraging. The rats tested with our proprietary Alzheimer's rat model took on features similar to the crippling dementia seen in a human's Alzheimer's brain, and then, by treating the rats with Caprospinol, the rat's brain cells bounced back with complete memory."

Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."

Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, Cancer, Heart disease, and Infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. Samaritan's Alzheimer's drug Caprospinol has received investigational new drug (IND) status from the FDA and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in various Eastern European countries.

Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.

The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business , please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

-0- CONTACT: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001 RichardBrown@SamaritanPharma.com


'"/>




Related medicine technology :

1. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
2. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
3. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):